Donanemab
Donanemab is a monoclonal antibody designed to target and clear amyloid-beta plaques in the brain, which are associated with Alzheimer's disease. By reducing these plaques, it aims to slow cognitive decline and improve brain health, making it relevant for longevity and cognitive optimization.
Member access required
Clinical protocols and outcomes data are available to AXIFI Members and Providers.